80650-46-0

Basic information

• Product Name: AcetaMide, 2-chloro-N-4-pyridinyl-
• Synonyms: AcetaMide, 2-chloro-N-4-pyridinyl-;2-Chloro-N-4-pyridinylacetamide;2-Chloro-N-(pyridin-4-yl)
• CAS NO: 80650-46-0
• Molecular Formula: C₇H₇ClN₂O
• Molecular Weight: 170.59628
• Mol File: 80650-46-0.mol
• Article Data: 17

Chemical Properties

• Melting Point: 210℃
• Boiling Point: 378℃
• Flash Point: 183℃
• Appearance: /
• Density: 1.341
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 11.67±0.70(Predicted)
• CAS DataBase Reference: AcetaMide, 2-chloro-N-4-pyridinyl-(CAS DataBase Reference)
• NIST Chemistry Reference: AcetaMide, 2-chloro-N-4-pyridinyl-(80650-46-0)
• EPA Substance Registry System: AcetaMide, 2-chloro-N-4-pyridinyl-(80650-46-0)

Safety Data

• Hazardous Substances Data: 80650-46-0(Hazardous Substances Data)

Usage

General Description

Acetamide, 2-chloro-N-4-pyridinyl- is a chemical compound with the molecular formula C7H7ClN2O. It is a derivative of acetamide and contains a chloro-substituted pyridine ring. Acetamide, 2-chloro-N-4-pyridinyl- is often used in the agricultural industry as an herbicide to control weeds and grasses in various crops. It works by inhibiting an important enzyme in the plant's growth process, leading to the death of the targeted plants. Acetamide, 2-chloro-N-4-pyridinyl- is considered to be a selective herbicide, meaning it targets specific types of plants while leaving others relatively unharmed. It is important to handle this chemical with care, as it can be toxic to humans and the environment if not used properly.

Upstream product

• 504-24-5 4-aminopyridine 
• 79-04-9 chloroacetyl chloride 

Downstream Products

• 303225-67-4 2-(4-nitrophenoxy)-N-pyridin-4-ylacetamide 
• 1196090-97-7 (R)-3-(1-Phenyl-cycloheptanecarbonyloxy)-1-(pyridin-4 ylcarbamoylmethyl)-1-azonia-bicyclo[2.2.2]octane chloride 
• 936632-78-9 1-deoxy-1-(6-{4-[(pyridin-4-ylcarbamoyl)methoxy]phenylamino}-9H-purin-9-yl)-N-ethyl-2,3-O-(1-methylethylidene)-β-D-ribofuranuronamide 
• 936633-18-0 2-(4-aminophenoxy)-N-pyridin-4-ylacetamide 

Relevant articles and documents

Synthesis and Structure–Activity Relationship of Thioacetamide-Triazoles against Escherichia coli

Infections due to Gram-negative bacteria are increasingly dangerous due to the spread of multi-drug resistant strains, emphasizing the urgent need for new antibiotics with alternative modes of action. We have previously identified a novel class of antibacterial agents, thioacetamide-triazoles, using an antifolate targeted screen and determined their mode of action which is dependent on activation by cysteine synthase A. Herein, we report a detailed examination of the anti-E. coli structure–activity relationship of the thioacetamide-triazoles. Analogs of the initial hit compounds were synthesized to study the contribution of the aryl, thioacetamide, and triazole sections. A clear structure–activity relationship was observed generating compounds with excellent inhibition values. Substitutions to the aryl ring were generally best tolerated, including the introduction of thiazole and pyridine heteroaryl systems. Substitutions to the central thioacetamide linker section were more nuanced; the introduction of a methyl branch to the thioacetamide linker substantially decreased antibacterial activity, but the isomeric propionamide and N-benzamide systems retained activity. Changes to the triazole portion of the molecule dramatically decreased the antibacterial activity, further indicating that 1,2,3-triazole is critical for potency. From these studies, we have identified new lead compounds with desirable in-vitro ADME properties and in-vivo pharmacokinetic properties.

NEW COMPOUNDS FOR TREATMENT OF DISEASES RELATED TO DUX4 EXPRESSION

The present invention relates to compounds for the treatment of diseases related to DUX4 expression, such as muscular dystrophies. It also relates to use of such compounds, or to methods of use of such compounds.

Design, synthesis of novel celastrol derivatives and study on their antitumor growth through HIF-1α pathway

Four series of hypoxia-inducible factor-1 alpha (HIF-1α) functioning derivatives stemming from modifications to the C-29 carboxyl group of celastrol were designed and synthesized, and their anticancer activities were evaluated. To address the structure and activity relationship of each derivative, extensive structural changes were made. HRE luciferase reporter assay demonstrated that 12 modified compounds showed superior HIF-1α inhibitory activity. Among them, compound C6 exhibited the best features: firstly, the strongest HIF-1α inhibitory activity (IC50 = 0.05 μM, 5-fold higher than that of celastrol); secondly, lower cytotoxicity (22-fold lower, C6-16.85 μM vs celastrol-0.76 μM). Thus, the safety factor of C6 was about 112 times higher than that of celastrol. Western blot assay indicated that C6 may inhibit the expression of HIF-1α protein in cells. Additionally, C6 hindered tumor cell cloning, migration and induced cell apoptosis. It is worth mentioning that in the mouse tumor xenograft model, C6 (10 mg/kg) displayed good antitumor activity in vivo, showing a better inhibition rate (74.03%) than the reference compound 5-fluorouracil (inhibition rate, 59.58%). However, the celastrol treatment group experienced collective death after four doses of the drug. Moreover, C6 minimally affected the mouse weight, indicating that its application in vivo has little toxic effect. H&E staining experiments show that it could also exacerbate the degree of tumor cell damage. The results of water solubility experiment show that the solubility of C6 is increased by 1.36 times than that of celastrol. In conclusion, C6 is a promising antitumor agent through HIF-1α pathway.